Istodax (romidepsin)
Published: Jun 4, 2009 6:51 pm
| Brand Name: | Istodax |
| Generic Name: | romidepsin |
| Code Name: | depsipeptide |
| Company: | Gloucester Pharmaceuticals/Celgene |
| FDA Clinical Phase: | 1/2 |
Description:
Istodax is a bicyclic depsipeptide antibiotic that binds and inhibits an enzyme known as histone deacetylase (HDAC). It alters the production of protein from DNA, inhibits the cell cycle, and causes cancer cells to die. Istodax, received FDA approval in November 2009 for the treatment of cutaneous T-cell lymphoma. Clinical trials studying the effects of Istodax and Velcade (bortezomib) in multiple myeloma are underway.
Clinical Trials:
Currently, there are several open clinical trials studying Istodax for the treatment of multiple myeloma.
Official Web site for Istodax: http://www.istodax.com/
Updated December 8, 2009
Related Articles:
- Anti-Cancer Drug Zolinza Shows Potential In Myeloma
- Immune System Cells Protect Myeloma Cancer Cells, Study Finds
- New Myeloma Drugs Target Different Mechanisms: Misfolded Proteins
- Study Examines Romidepsin-Velcade Combination Treatment In Myeloma Patients (ASCO 2009)
- IMW 2009 – Elotuzumab And Panobinostat Clinical Trials With Velcade
Leave a comment